Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C03 DIURETICS
C03X OTHER DIURETICS
C03XA Vasopressin antagonists
C03XA02 Conivaptan
D01236 Conivaptan hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01506 Arginine vasopressin receptor 2 (AVPR2) antagonist
DG00276 Conivaptan
D01236 Conivaptan hydrochloride
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG00276 Conivaptan
D01236 Conivaptan hydrochloride
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG00276 Conivaptan
D01236 Conivaptan hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Vasopressin
AVPR1A
D01236 Conivaptan hydrochloride (JAN/USAN)
AVPR2
D01236 Conivaptan hydrochloride (JAN/USAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01236
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01236
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01236
Drug groups [BR:br08330]
Cardiovascular agent
DG01506 Arginine vasopressin receptor 2 (AVPR2) antagonist
DG00276 Conivaptan
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG00276 Conivaptan
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG00276 Conivaptan